α2-adrenoreceptors profile modulation. 2.1 Biphenyline analogues as tools for selective activation of the α2C-subtype

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6160-6173

  Gentili, Francesco ^a   Ghelfi, Francesca ^a   Giannella, Mario ^a   Piergentili, Alessandro ^a   Pigini, Maria ^a   Quaglia, Wilma ^a   Vesprini, Cristian ^a   Crassous, Pierre Antoine ^b   Paris, Hervé ^b   Carrieri, Antonio ^c  

^a UNIVERSITY OF CAMERINO   (Italy)

^b CHU RANGUEIL   (France)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)ETHOXY]BIPHENYL 3 OL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LIGAND; RECEPTOR SUBTYPE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BIPHENYL COMPOUNDS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXAZOLES; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-2; SEQUENCE HOMOLOGY, AMINO ACID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 9744260987     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0408215     Document Type: Article

References (69)

1. For part 1, see ref 36.
2. Ruffolo, R. R., Jr., Ed.; Adrenoceptors: Structure, Function and Pharmacology; Harwood Academic Publisher GmbH: Luxembourg, 1995.
3. Hoffman, B. B.; Lefkowitz, R. J. Radioligand Binding Studies of Adrenergic Receptors: New Insights into Molecular and Physiological Regulation. Annu. Rev. Pharmacol. Toxicol. 1980, 20, 581-608.
4. i Protein Subtypes Regulate a Single Effector Mechanism. Mol. Pharmacol. 1991, 40, 707-711.
5. 8. J. Biol. Chem. 1992, 267, 15795-15801.
6. Hieble, J. P.; Bondinell, W. E.; Ruffolo, R. R., Jr. α- and β-Adrenoceptors: From the Gene to the Clinic. 1. Molecular Biology and Adrenoceptor Subclassification. J. Med. Chem. 1995, 38, 3415-3444.
7. (a) Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R., Jr.; Trendelenburg, U. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol. Rev. 1994, 46, 121-136.
8. 2-Adrenoceptors. Pharmacol. Commun. 1995, 6, 91-97.
9. 2-Adrenergic Receptor Subtype Diversity: One Receptor Is Not Enough. Am. J. Physiol. Regul. Integr. Comput. Physiol. 2002, 283, R287-R295.
10. 2A Adrenoceptor Antagonist, BRL 48962, and its Characterization at Cloned Human α-Adrenoceptors. Bioorg. Med. Chem. 1995, 3, 1693-1698.
11. 2C-Adrenoceptors Mediate Contractile Responses to Noradrenaline in the Human Saphenous Vein. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 406-411.
12. 2B Adrenergic Receptor Subtypes: Antagonist Binding in Tissues and Cell Lines Containing Only One Subtype. J. Pharmacol. Exp. Ther. 1998, 245, 600-607
13. 2-Adrenoceptors in Rabbit Iris. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 347, 394-401.
14. 2B-Adrenoceptor. WO 03/008387 A1, 2003; Chem. Abstr. 2003, 138, 122655.
15. 3H]MK912 and Subtype-Selective Drugs. Brain Res. 1997, 770, 261-266.
16. 2A- Selective Compound. Eur. J. Pharmacol. 1991, 202, 235-243.
17. 2-Adrenoceptor-Subtype Function. Trends Pharmacol. Sci. 1997, 18, 211-219.
18. 2-Adrenergic Receptors. J. Pharmacol. Exp. Ther. 2000, 293, 1-7.
19. 2A-Adrenergic Receptor Subtype. Science 1996, 273, 801-803.
20. 2A- Adrenergic Receptor via "hit and run" Gene Targeting Reveals the Role of This Subtype in Sedative, Analgesic, and Anesthetic-Sparing Responses in vivo. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9950-9955.
21. 2-Adrenoceptor Subtypes in the Antinociceptive, Sedative and Hypothermic Action of Dexmedetomidine in Transgenic Mice. Br. J. Pharmacol. 1997, 122, 1339-1344.
22. 2A Adrenergic Receptor Abolishes the Antiepileptogenic Action of Endogenous Norepinephrine. J. Neurosci. 1998, 18, 2004-2008.
23. 2 Agonists and Is Necessary for Spinal Adrenergic-Opioid Synergy. J. Neurosci. 1997, 17, 7157-7165.
24. 2A Noradrenergic Agonist, Guanfacine, Improves Delayed Response Performance in Young Adult Rhesus Monkeys. Psychopharmacol. 1998, 136, 8-14.
25. 2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task. Neuropsychopharmacol. 2000, 23, 240-249.
26. 2-Adrenergic Receptor Subtypes b and c. Science 1996, 273, 803-805.
27. 2B-Adrenergic Receptor in the Development of Salt-Induced Hypertension. Hypertension 1999, 33, 14-17.
28. Rohrer, D. K.; Kobilka, B. K. Insights from in Vivo Modification of Adrenergic Receptor Gene Expression. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 351-373.
29. 2-Adrenoceptors in Human Vascular Smooth Muscle Cells. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, 59-67.
30. 2C, Inhibit Transmitter Release in the Brain of Gene-Targeted Mice. Neuroscience 2002, 109, 819-826.
31. 2C-Adrenoceptor Overexpression Disrupts Execution of Spatial and non-Spatial Search Patterns. Neuroscience 1999, 88, 1187-1198.
32. 2C- Adrenoceptor Gene. Eur. J. Neurosci. 1999, 11, 599-603.
33. 2C-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice. J. Neurosci. 1998, 18, 3035-3042.
34. 2C-Adrenergic Receptor Subtype. Neuroscience 1998, 86, 959-965.
35. 2C-Adrenergic Receptors Mediate Spinal Analgesia and Adrenergic-Opioid Synergy. J. Pharm. Exp. Ther. 2002, 300, 282-290.
36. Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M.; Giannella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, S. K.; Brasili, L. Imidazoline Receptors: Qualitative Structure-Activity Relationship and Discovery of Tracizoline and Benzazoline. Two Ligands with High Affinity and Unprecedent Selectivity. Bioorg. Med. Chem. 1997, 5, 833-841.
37. Pigini, M.; Quaglia, W.; Gentili, F.; Marucci, G.; Cantalamessa, F.; Franchini, S.; Sorbi, C.; Brasili, L. Structure-Activity Relationship at α-Adrenergic Receptors within a Series of Imidazoline Analogues of Cirazoline. Bioorg. Med. Chem. 2000, 8, 883-888.
38. 2-Adrenoreceptors Profile Modulation and High Antinociceptive Activity of (S)-(-)-2-[1-(Biphenyl- 2-yloxy)ethyl]4,5-dihydro-1H-imidazole. J. Med. Chem. 2002, 45, 32-40.
39. 2-IBS Selectivity within a Series of 2-Phenoxymethylimidazoline Analogues. J. Med. Chem. 2003, 46, 2169-2176.
40. 2-Adrenoceptors. Science 2004, 67, 87-96.
41. Molderings, G. J. Imidazoline Receptors: Basic Knowledge, Recent Advances and Future Prospects for Therapy and Diagnosis. Drugs Future 1997, 22, 757-772.
42. Eglen, R. M.; Hudson, A. L.; Kendall, D. A.; Nutt, D. J.; Morgan, N. G.; Wilson, V. G.; Dillon, M. P. "Seeing through a Glass Darkly": Casting Light on Imidazoline "I" Sites. Trends Pharmacol. Sci. 1998, 19, 381-390.
43. Magnien, E.; Testa, F.; Shapiro, S. L. Substituted 2-Phenoxypropionic and -butyric Acids and Derivatives. J. Med. Chem. 1966, 9, 449-450.
44. Miyaura, N.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
45. (a) Colbert, J. C.; Lacy, R. M. The Effect of Substituent Groups upon the Course of the Condensation Reaction between Benzenediazonium Salts and Phenols. J. Am. Chem. Soc. 1946, 68, 270-271.
46. (b) Downie, I. M.; Heaney, H.; Kemp, G.; King, D.; Wosley, M. Cyclisation Reactions of 2-Substituted Biphenyl-2′-yldiazonium Salts Leading to O-Alkyldibenzofuranium and S-Alkyldibenzothiophenium Salts: Modified Meerwein Reagents. Tetrahedron 1992, 48, 4005-4016.
47. Deschamps, B.; Seyden-Penne, J. Effet de Solvant sur la Stereochimie de la Reaction de Darzens. III. Etude de la Condensation du Chloracetonitrile et des Aldehydes Aromatiques en Milieu Basique. Tetrahedron 1971, 27, 3959-3964.
48. Cullen, B. R. Use of Eukaryotic Expression Technology in the Functional Analysis of Cloned Genes. Methods Enzymol. 1987, 152, 684-704.
49. 3H]-RX 821002 Binding and Definition of Additional Selective Drugs. Eur. J. Pharmacol. 1994, 252, 43-49 and references therein.
50. 50) of an Enzimatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
51. 2-Adrenoceptor Subtypes with Cytosensor Microphysiometry. Eur. J. Pharmacol. 1999, 385, 247-253.
52. Bairoch, A.; Apweiler, R. The SWISS-PROT Protein Sequence Data Bank and Its Supplement TrEMBL in 1998. Nucleic Acids Res. 1998, 26, 38-42.
53. Ballesteros, J. A.; Weinstein, H. Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors. Methods Neurosci. 1995, 25, 366-428.
54. Li, J.; Edwards, P.; Burghammer, M.; Villa, C.; Schertler, G. F. X. Structure of Rhodopsin in a Trigonal Crystal Form, to be published. The rhodopsin structure (PDB code 1GZM) is available at the following URL http://www.rcsb.org.
55. Sali, A.; Blundell, T. L. Comparative Protein Modelling by Satisfaction of Spatial Restraints. J. Mol. Biol. 1993, 234, 779-815.
56. Kelley, L.; Gardner, S. P.; Sutcliffe, M. J. An Automated Approach for Clustering an Ensemble of NMR-Derived Protein Structures into Conformationally Related Subfamilies. Protein Eng. 1996, 9, 1063-1065.
57. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A Program to Check the Stereochemical Quality of Protein Structures. J. Appl. Crystallogr. 1993, 26, 283-291.
58. McMartin, C.; Bohacek, R. S. QXP: Powerful, Rapid Computer Algorithms for Structure-Based Drug Design. J. Comput. Aided Mol. Des. 1997, 11, 333-344.
59. 2A-Adrenergic Receptors: Identification of Amino Acids Involved in Ligand Binding and Receptor Activation by Agonists. Mol. Pharmacol. 1991, 40, 168-179.
60. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" Substituent Constants for Structure-Activity Correlations. J. Med. Chem. 1973, 16, 1207-1216.
61. 2C-Adrenergic Receptor by cAMP. Mol. Pharmacol. 2000, 58, 821-827.
62. 2- Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
63. 1b-Adrenergic Receptor is Initiated by Disruption of an Interhelical Salt Bridge Constraint. J. Biol. Chem. 1996, 271, 28318-28323.
64. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Sigal, I. S.; Dixon, R. A. Identification of Two Serine Residues Involved in Agonist Activation of the β-Adrenergic Receptor. J. Biol. Chem. 1989, 264, 13572-13578.
65. 1-Adrenergic Receptor Agonist Binding and Activation. J. Biol. Chem. 1996, 271, 6322-6327.
66. 1d-Adrenergic Receptor Activation: A Molecular Dynamics and Docking Study. Proteins 2001, 43, 382-394.
67. 2-Adrenergic Receptor Activation. Modulation of the Proline Kink in Transmembrane 6 by a Rotamer Toggle Switch. J. Biol. Chem. 2002, 277, 40989-40996.
68. Schaak, S.; Devedjian, J. C.; Paris, H. Use of Eukaryotic Vectors for the Expression of Adrenergic Receptors. Methods Mol. Biol. 2000, 126, 189-206.
69. Bradford, M. M. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 1976, 72, 248-254.